On We The People, we debate if clinical trials in India have too many or few safeguards. Are poor still vulnerable? And do the latest regulatory norms water down the safety norms? With government waiving Phase III trials for drugs that are already tested in countries that have robust regulatory mechanism, does the pursuit of new drugs and vaccines have very few safeguards?
